Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD371-YSNVZ-IL18 CAR T cells
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
CD371-YSNVZ-IL18 CAR T cells is an investigational "armored" chimeric antigen receptor (CAR) T-cell therapy designed to treat relapsed or refractory acute myeloid leukemia (AML). The therapy specifically targets C-type lectin domain family 12 member A (CLEC12A, also known as CD371 or CLL-1), an antigen highly expressed on AML blasts and leukemic stem cells but typically absent on healthy hematopoietic stem cells, thereby minimizing myelosuppressive side effects. These CAR T-cells are further engineered to secrete Interleukin-18 (IL-18), a proinflammatory cytokine intended to enhance the expansion, persistence, and anti-tumor efficacy of the T cells while modulating the immunosuppressive tumor microenvironment. The "YSNVZ" designation refers to the specific binder or single-chain variable fragment (scFv) used to recognize the CD371 epitope.
- Other names
- CD371-YSNVZ-IL18 CAR-T cellsCD-371-YSNVZ-IL18 CAR-T cellsCD 371-YSNVZ-IL18 CAR-T cellsCLEC12A-YSNVZ-IL18 CAR T cellsCLEC-12A-YSNVZ-IL18 CAR T cellsCLEC 12A-YSNVZ-IL18 CAR T cellsCLL-1-YSNVZ-IL18 CAR T cellsCLL1-YSNVZ-IL18 CAR T cellsCLL 1-YSNVZ-IL18 CAR T cells
02
Targets
CLEC12AIL-18R (Interleukin-18 receptor complex)
Beyond the preview
Go deeper on CD371-YSNVZ-IL18 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD371-YSNVZ-IL18 CAR T cells.